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Plasmacytoid DCs (pDCs) are a distinct popula-
tion of DCs in the peripheral blood and sec-
ondary lymphoid organs and are characterized 
by their plasma cell–like morphology and 
unique surface receptor phenotype (1). These 
cells play an important role in innate antiviral 
immunity by rapidly secreting abundant type I 
IFNs (IFNα, β, ω, λ) after exposure to various 
DNA and RNA viruses (1, 2). Type I IFNs 
produced by pDCs promote the function of 
NK cells, B cells, T cells, and myeloid DCs 
(mDCs) during the initial immune response 
(3–5). After activation, pDCs diff  erentiate into 
a unique type of mature DCs, capable of directing 
T cell responses with considerable fl  exibility 
(3, 4). Thus, pDCs represent a critical link be-
tween innate and adaptive immune responses.
The unique ability of pDCs to sense and 
respond rigorously to microbes by rapidly pro-
ducing large amounts of type I IFN is under-
lined by their expression, in contrast with 
mDCs and other immune cells, of a selective 
set of toll-like receptors (TLRs), in par  ticular 
TLR7 and TLR9 (6). Recent studies have 
  revealed an intracellular multiprotein com-
plex that likely includes TLR9/7–MyD88–
IRAK1/4–TRAF6–IRF7 and a complicated 
spatiotemporal signaling scheme in pDCs (7, 8). 
Because both TLR7 and TLR9 are located 
in the endosomal compartment of pDCs, how 
these cells sense the external   microenvironment 
by surface receptors has remained elusive. We, 
therefore, performed a global gene expression 
analysis of human pDCs, in comparison with 
the other major human immune cell types. 
Human pDCs selectively express ILT7 (also 
named CD85g and LILRA4) transcripts as well 
as IL-3R (CD123) and BDCA-2, as previously 
reported (9–11).
ILT7 is a member of the immunoglobulin-
like transcripts (ILTs), or leukocyte immuno-
globulin-like receptor (LIR) gene family (12), 
which comprises at least 13 loci. ILTs are 
  predominantly expressed on the surface of 
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  myelomonocytic cells, including macrophages and DCs. Al-
though the extracellular Ig domains are responsible for ligand 
binding, the residues within the transmembrane and cyto-
plasmic domains defi  ne two functional classes of ILTs: the 
inhibitory ILTs contain the immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) in the cytoplasmic domain, whereas 
the activating ILTs lack any intrinsic signaling motifs and rely 
on association with transmembrane adapter proteins bearing 
immunoreceptor-based tyrosine activation motif (ITAM). 
  Certain ILTs, such as ILT2 and ILT4, bind to classical and non-
classical MHC class I proteins (13). The ITIM-containing 
ILT2 inhibits signaling through the TCR in T cells (14) and 
enhances the inhibitory eff  ects of killer cell Ig–like   receptors 
(KIRs) in NK cells (13). In contrast, ILT1 associates with 
FcεRIγ and activates eosinophils to release cytotoxic granule 
proteins, cytokines, and lipid mediators (15).
ILT7 encodes a surface receptor that is preferentially tran-
scribed by human pDCs. This molecule contains four extra-
cellular Ig domains and has a positively charged residue within 
the transmembrane region, which potentially allows it to as-
sociate with membrane-anchored adapter proteins. In this 
study, we report that ILT7 and FcεRIγ form a receptor 
complex that is specifi   c for human pDCs and transduces 
ITAM-mediated signals that negatively modulate TLR-in-
duced type I IFN production by human pDCs.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
ILT7 mRNA is specifi  cally expressed by pDCs
To determine the expression profi  le of ILT7 in human 
  leukocytes, we searched our established expression database, 
which included the major immune cell types in peripheral 
blood. Strikingly, ILT7 transcripts were expressed abundantly 
and exclusively by human pDCs (Fig. 1 A). pDCs also ex-
pressed ILT2 and ILT3; however, these receptors were also 
expressed by other cell types (Fig. 1 A). To verify this fi  nd-
ing, we performed quantitative RT-PCR analysis on several 
cell types from multiple healthy donors. Consistently, human 
pDCs uniquely expressed ILT7 mRNA (Fig. 1 B).
ILT7 uses Fc𝗆RI𝗄 as an adapter
The positively charged arginine residue at position 449 is lo-
cated within the predicated transmembrane segment of the 
ILT7 protein. To look for the adapter proteins interacting with 
ILT7, we examined the expression of the transmembrane 
Figure 1.  Human pDCs preferentially express ILT7 and three trans-
membrane signaling adapters. (A) The relative expression of ILT family 
members on peripheral blood leukocytes was compared by plotting the 
values extracted from the gene expression database. A value <1 indicated 
the absence of gene expression. (B) The relative gene expression of ILTs on 
different cell types from three healthy donors was determined by quanti-
tative RT-PCR analysis. The expression was normalized with the level of 
total PBMCs. The median expression is marked by a horizontal bar. (C) The 
expression levels of known transmembrane signaling adapters in pDCs 
were plotted using the values extracted from the gene expression data-
base. (D) The relative expression of FcεRIγ, DAP12, and DAP10 was deter-
mined from three healthy donors by quantitative RT-PCR analysis. The 
expression was normalized with S18 and multiplied by 1,000. The median 
expression is marked by a horizontal bar.JEM VOL. 203, June 12, 2006  1401
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adapters in human pDCs from the expression database (Fig. 
1 C). Although lacking the expression of ITAM-bearing 
components found in TCR and B cell receptors (BCRs), 
pDCs expressed two ITAM-bearing adapters (i.e., FcεRIγ 
and DAP12). DAP10, a non-ITAM adapter, which signals 
via a YINM motif permitting activation of PI3 kinase, was 
also transcribed in pDCs (Fig. 1 C). We further confi  rmed 
the expression of these adapters by RT-PCR analysis of three 
healthy donors (Fig. 1 D).
To determine which adapter pairs with ILT7, we used an 
“adapter trap” reporter cell system in which mouse BaF/3 
pro–B cells were stably transfected with FcεRIγ, DAP12, or 
DAP10. ILT7 stabilized the surface expression of FcεRIγ, but 
neither DAP12 nor DAP10 (Fig. 2 A). Similarly, FcεRIγ en-
hanced the cell surface expression of ILT7 (Fig. 2 A). As a 
positive control for DAP10 and DAP12, we used a mouse 
NKG2D variant that could pair with either DAP12 or DAP10 
(16). Additionally, ILT7 and FcεRIγ were coimmunoprecip-
itated from a lysate of BaF/3 cells transfected with HA-tagged 
ILT7 and FLAG-tagged FcεRIγ (Fig. 2 B). Thus, our results 
demonstrate that ILT7 associates with the ITAM-containing 
signaling adapter FcεRIγ to form a stable receptor complex.
ILT7 is a pDC-specifi  c receptor
To confi  rm the expression of the ILT7 protein, we generated 
a mAb that recognizes a mouse T cell line transfected with 
human ILT7 (Fig. 3 A). In total PBMCs, anti-ILT7 mAb 
stained a rare cell population of non–T, non–B, nonmono-
cyte, and non–NK cells (unpublished data). When double 
stained with mAb against pDC marker BDCA2, almost all the 
ILT7+ cells were BDCA2high (Fig. 3 B), suggesting that the 
circulating blood pDCs preferentially express ILT7. When 
activated by CpG or treated with IL-3, pDCs expressed lower 
levels of ILT7 (Fig. 3 C), consistent with the reported down-
regulation of ILT7 mRNA in activated pDCs (10, 11).
ILT7 triggers ITAM signaling
To reveal the cellular signals transduced by ILT7, we introduced 
a human ILT7–FcεRIγ complex into a mouse T cell hybrid-
oma line that contained an intracellular NFAT–GFP construct 
(Fig. 4 A). Cross-linking ILT7 with immobilized anti-ILT7 
mAb resulted in GFP expression, indicating that ILT7-FcεRIγ 
is able to activate NFAT, similar to the eff  ect of TCR activation. 
The immobilized isotype-matched control antibody did not 
  activate the cells under the same conditions (Fig. 4 A). When the 
same experiment was conducted in NFAT-GFP reporter cells 
expressing ILT7 alone (without FcεRIγ), cross-linking ILT7 
did not induce GFP expression, which illustrated again the 
  requirement of FcεRIγ for ILT7 to signal (unpublished data).
To evaluate the signaling events in primary human pDCs 
induced by ILT7 activation, we cross-linked ILT7 on freshly 
isolated pDCs and analyzed the phosphorylation status of two 
key types of protein tyrosine kinases (PTKs) by Western blot 
analysis (Fig. 4 B). After ITAM-mediated activation, two 
core tyrosine residues within the ITAMs are phosphorylated 
by PTKs of the Src family kinases. The tyrosine-phosphory-
lated ITAMs associate with the Src homology 2 (SH2) do-
mains of spleen tyrosine kinase (Syk)-family kinases to initiate 
the well-orchestrated cascade of downstream events. Human 
pDCs express several members of the Src family kinases and 
Syk, but not ZAP70 (unpublished data). Shortly after ILT7 
activation, both Src family kinases and Syk were phosphory-
lated (Fig. 4 B), indicating the onset of ITAM-mediated 
  signaling in pDCs. In contrast, cross-linking with neither 
the isotype-matched control antibody nor the mAb against 
BDCA4, another surface molecule expressed on pDCs, phos-
phorylated these kinases under the same conditions.
Next, we analyzed one of the important cellular activa-
tion events that occurs downstream of ITAM-mediated 
  signaling: calcium infl  ux. Cross-linking of ILT7 eff  ectively 
triggered prominent intracellular calcium mobilization in 
Figure 2.  ILT7 associates with Fc𝗆RI𝗄. (A) BaF/3 cells stably trans-
fected with FLAG-FcεRIγ (top), -DAP12 (middle), or -DAP10 (bottom) 
were transduced with HA-ILT7 (center column) or with the vector alone 
(left column). Cells were stained for FLAG and HA and analyzed by fl  ow 
 cytometry. HA-tagged human KIR2DL4 or a mouse NKG2D variant was trans-
duced into the BaF/3 cells as positive controls (right column). (B) Lysate 
from parental BaF/3 cells or cells expressing ILT7-HA and FcεRIγ-FLAG 
was precipitated with IgG1, anti-HA, or anti-FLAG mAbs. Western blot 
(WB) was performed with anti-HA or anti-FcεRIγ Ab. A fraction of the 
original lysate was run as control. Notably, ILT7-HA ran as two bands, 
likely refl  ecting differentially processed isoforms.1402  PDC-SPECIFIC ILT7–FCεRIγ INHIBITS TLR RESPONSES | Cao et al.
  human primary pDCs (Fig. 4 C). This activity was greatly 
  reduced by PP2, a compound that interferes with the func-
tion of Src family kinases, but was not aff  ected by an inactive 
control compound PP3 (Fig. 4 C). In addition, an inhibitor 
specifi  c to Syk kinase completely abolished the intracellular 
calcium activity in ILT7–cross-linked pDCs (Fig. 4 C). 
Therefore, the ILT7–FcεRIγ complex is capable of activating 
the ITAM pathways in human pDCs.
ILT7–Fc𝗆RI𝗄 inhibits pDCs’ TLR responses
An important role of the ILT molecules is to modulate the 
function of other immune receptors (12). pDCs expressing 
TLR9 and TLR7 respond to CpGs and viruses by producing 
large amounts of type I IFN, as well as other proinfl  ammatory 
cytokines (6). We examined how ILT7 triggering infl  uences 
TLR responses in human pDCs. When ILT7 was cross-linked, 
pDCs stimulated by the TLR9 ligand CpG oligonucleotide 
(ODN) produced less IFNα and TNFα, in comparison with 
medium control or isotype-matched control Ab (Fig. 5 A). 
However, ILT7 cross-linking did not aff  ect the surface matu-
ration phenotype of pDCs, as measured by CD80 and CD86 
expression (Fig S1, available at http://www.jem.org/cgi/
content/full/jem.20052454/DC1). Cross-linking of surface 
BDCA4 under the same conditions did not alter the TLR 
responses (Fig. 5 A), consistent with a published report (17). 
As a positive control, preincubation of pDCs with anti-
BDCA2 mAb (5 μg/ml) dramatically reduced the TLR-me-
diated responses. Interestingly, ILT7 cross-linking eff  ectively 
reduced TLR response even after pDCs were preexposed to 
CpG up to 1 h, which was analogous to the eff  ects of BDCA2 
cross-linking (Fig. 5 B). Moreover, when we activated pDCs 
with inactivated infl  uenza virus (Flu), a ligand for TLR7 (18), 
ILT7 cross-linking similarly inhibited the production of both 
IFNα and TNFα (Fig. 5 A).
To confi  rm this observation, we examined the intra-
cellular IFNα and TNFα levels in the CpG-activated pDCs 
that were cross-linked under similar conditions. Consis-
tently, ILT7 cross-linking specifi  cally decreased the amount 
of intracellular IFNα as well as TNFα (Fig. 5 C). Last, we 
Figure 3.  Anti-ILT7 mAb specifi  cally stains peripheral blood pDCs. 
(A) Mouse 2B4 T cell hybridoma expressing human FcεRIγ (top) was 
transduced with HA-ILT7 (bottom). The cells were stained with an isotype-
matched control Ab (IgG1), anti-HA, or anti-ILT7 mAb. (B) Total PBMCs 
were stained with IgG1 (left) or anti-ILT7 (right) and anti-BDCA2 mAb. 
Representative results from the analysis of multiple healthy donors are 
shown. (C) Surface ILT7 was measured on freshly isolated, IL-3–treated, 
or CpG-treated pDCs at various times after culture. Mean fl  uorescence 
intensity of each sample is indicated (top right).
Figure 4.  Cross-linking of ILT7/Fc𝗆RI𝗄 activates ITAM-mediated 
signaling. (A) 2B4 T cell hybridoma expressing FcεRIγ and ILT7 was cross-
linked with mouse IgG1 or anti-ILT7 mAb and analyzed for NFAT-activated 
GFP expression. Cells cultured in medium alone were also analyzed. 
(B) Freshly isolated human pDCs were cross-linked with mouse IgG1, anti-
ILT7, or anti-BDCA4 mAb and the cell lysates were analyzed by Western 
blotting. (C) The kinetics of intracellular calcium fl  ux in human pDCs when 
cross-linked (arrow) by control (IgG1) or anti-ILT7 Ab. As indicated, cells 
were preincubated for 30 min with 50 μM of PP2, 50 μM of PP3, or 
10 μM of Syk inhibitor (EMD Biosciences) before cross-linking.JEM VOL. 203, June 12, 2006  1403
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evaluated the amount of type I IFN transcripts from both 
CpG and Flu-activated pDCs that were cross-linked with 
anti-ILT7 or control mAbs. ILT7 cross-linking consistently 
reduced the transcription of all four subtypes of type I IFN 
analyzed (i.e., IFNα1, IFNα2, IFNα4 and IFNβ) (Fig. 5 D). 
Thus, ILT7 activation by mAb cross-linking signifi  cantly 
down-regulated the TLR-induced IFN and cytokine re-
sponses in pDCs.
We have shown that the ILT7–FcεR1γ complex repre-
sents the fi  rst human pDC-specifi  c ITAM-containing recep-
tor complex. Cross-linking of the surface ILT7–FcεR1γ 
complex on pDCs elicited activating signals, including phos-
phorylation of Src family kinases and Syk kinase, and induced 
a robust intracellular calcium mobilization. However, rather 
than enhancing the production of cytokines induced by stim-
ulation of TLR, ILT7 functioned as a negative regulator of 
these TLR-mediated responses. Inhibition of TLR-induced 
human pDC activation by ITAM-receptor signaling has been 
documented in several prior studies. For example, cross-linking 
of the high affi   nity IgE receptor, which signals via FcεRIγ, 
also inhibits CpG-induced type I IFN production by human 
pDCs (19, 20). Additionally, Fuchs et al. reported that cross-
linking NKp44, a receptor signaling through the ITAM-
bearing DAP12 adapter, inhibited CpG-induced IFN-α 
production (20, 21). In mice, mAb cross-linking of Siglec-H, 
another DAP12-associated receptor, reduced type I IFN 
  production by pDCs in vitro and in vivo (22). These fi  nd-
ings support and extend the prior studies reporting that 
Figure 5.  ILT7 cross-linking inhibits TLR responses by pDCs. 
(A) Human pDCs were cross-linked with various Abs before stimulation 
by CpG (left) or Flu virus (right). The levels of the secreted IFNα and TNFα 
in a triplicate assay from a representative donor are shown. (B) Purifi  ed 
pDCs were cultured with CpG for 1 h (left) or 30 min (second panel from 
left) at 37°C before being cross-linked. Alternatively, CpG was added at 
the same time as (second panel from right) or 30 min after (right) cells 
were cross-linked by various mAbs. The amounts of IFNα and TNFα in the 
supernatant after 18 h of culture are shown. (C) The amounts of IFNα and 
TNFα were determined by intracellular staining of CpG-activated pDCs. 
The percentage of the double-positive cell population is indicated. (D) The 
amounts of type I IFN transcripts were determined by quantitative RT-PCR 
analysis. The expression is shown as the relative level of transcription com-
pared with unstimulated pDCs.1404  PDC-SPECIFIC ILT7–FCεRIγ INHIBITS TLR RESPONSES | Cao et al.
ITAM-mediated signaling can suppress the response of mouse 
macrophages to TLR ligands in vivo and in vitro (22, 23).
It is not clear how ITAM and TLR pathways intersect at 
the molecular level in human pDCs. Schroeder et al. demon-
strated that IgE receptor cross-linking inhibited TLR9 ex-
pression in pDCs, which may explain in part the reduced 
CpG responses by these cells (19). Alternately, one possible 
mechanism may involve a bifunctional role of the ITAM of 
FcεRIγ. Specifi   cally, under diff   erent conditions, FcεRIγ 
may function as an activating molecule by recruiting Syk, or 
alternatively act as an inhibitory receptor by recruiting SHP-1 
and subsequently impairing protein tyrosine phosphorylation 
in the absence of sustained receptor aggregation (23, 24). 
Similarly, the downstream adapter protein LAB/NTAL may 
play either positive or negative roles in regulating FcεRIγ-
mediated signaling under diff  erent conditions (25, 26). It will 
be important to examine in detail the biochemical mecha-
nism of this inhibitory eff  ect by ITAMs on TLR signaling.
pDCs are critically responsible for the massive and rapid 
type I IFN production elicited by viral infections. Control-
ling the type and the magnitude of this response is important 
in resolving disease without harming healthy tissue. Elevated 
levels of IFNα and up-regulated expression of IFN-respon-
sive genes were found in the peripheral blood of systemic 
  lupus erythematosus patients, where pDCs were presumably 
activated by chromatin-containing immune complexes (27). 
Therefore, the eff  ective inhibition of pDCs and down-regu-
lation of their constitutive type I IFN production, possibly 
through the ILT7–FcεRIγ receptor complex, may present 
a plausible therapeutic approach.
MATERIALS AND METHODS
Establishment of human leukocyte expression database. This study 
was approved by the institutional review board for human research at the 
M.D. Anderson Cancer Center. Human peripheral DCs, B cells, T cells, 
monocytes, and monocyte-derived DCs were prepared as described previ-
ously (28). CD56+CD4−CD14−CD19−CD69− NK cells were isolated by 
fl  ow cytometry. Neutrophils, eosinophils, basophils, and blood CD34+ hema-
topoietic progenitor cells (HPCs) were isolated as described previously (29). 
RNA preparation and microarray hybridization was performed as described 
previously (27, 28). The Positional Dependent Nearest Neighbor model (30) 
was used to estimate the gene expression values from the probe intensity values. 
The fi  nal expression output was normalized with the numerical value of one 
representing the estimated threshold of basal expression.
Quantitative RT-PCR analysis. Reverse transcription and   quantitative 
PCR was performed as described previously (27, 28).   Oligonucleotide 
primers used are listed in Table S1 (available at http://www.jem.org/cgi/
content/full/jem.20052454/DC1).
Cloning and expression of ILT7 and transmembrane adapters. ILT7 
was cloned from pDC cDNAs. A retroviral vector expressing ILT7 with an 
HA tag was used to transduce BaF/3 cells expressing FLAG-tagged human 
FcεRIγ, DAP12, or DAP10 (16).
Generation of ILT7 mAb and PBMC staining. 6–8-wk-old BALB/c 
mice were immunized with ILT7–FcεRIγ-transfected 2B4 cells. Hybrid-
oma clones secreting mAb that specifi  cally stained ILT7+ cells were estab-
lished. mAb 17G10.2 against ILT7 (IgG1) was purifi  ed and fl  uorochrome 
  conjugated using mAb-labeling kits obtained from Invitrogen. PBMCs 
were stained with anti-BDCA2–FITC (Miltenyi Biotec) and Alexa Fluor 
A647–labeled anti-ILT7 mAb.
NFAT-GFP reporter assay. HA-tagged ILT7 was transduced into the 
2B4 NFAT-GFP reporter cells (H. Arase, Osaka University, Osaka, Japan) 
with or without mouse FcεR1γ. The cells were cultured on Ab-coated 
plates (10 μg/ml) for 16 h and analyzed for GFP expression.
Western blot analysis of protein tyrosine phosphorylation. pDCs iso-
lated using BDCA4 cell isolation kit (Miltenyi Biotec) were incubated 
with mouse IgG1 (eBioscience), anti-ILT7, or anti-BDCA4 mAb (IgG1; 
Miltenyi Biotec) and cross-linked with F(ab′)2 goat anti–mouse IgG (Jackson 
ImmunoResearch Laboratories) for 2 min. Western blot was performed with 
an anti-phospho–Src family Ab, anti-phospho–Syk Ab, anti-nonphospho–
Src family Ab, anti-Syk Ab (Cell Signaling Technology), and anti–β-actin 
mAb (Sigma-Aldrich).
Calcium infl  ux  assay. pDCs preloaded with Fluo4- and Fura Red-AM 
  (Invitrogen) were cross-linked as described in the previous paragraph and ana-
lyzed on a FACSAria (BD Biosciences) and by FlowJo software (Tree Star).
ILT7 cross-linking pDCs on pDCs in culture. pDCs isolated by fl  ow 
cytometry (CD4+CD11c−CD3−CD14−CD16−CD19−CD56−) were incu-
bated in the Ab-coated wells (10 μg/ml) for 30 min before stimulation with 
0.1 μM of CpG 2216 or heat-inactivated Flu at a multiplicity of infection 
of 3, unless otherwise specifi  ed. Cells and supernatants were harvested 18 h 
later for RT-PCR and ELISA. ELISA kits used were human IFNα (Bender 
MedSystems) and TNFα (R&D Systems). Intracellular cytokine staining was 
performed after 6 h of culture with CpG as described previously (28). Cells 
were stained with anti–IFN-α–FITC Ab (Chromaprobe), anti-CD123–PE 
Ab (eBioscience), and anti-TNFα–allophycocyanin Ab (BD Biosciences).
Online supplemental material. Fig. S1 shows that ILT7 cross-linking 
does not aff  ect pDC maturation. Surface CD80 and CD86 expression was 
measured by fl  ow cytometry on pDCs cultured with CpG or IL-3. Table S1 
lists all the oligonucleotide primers used in this study. Fig. S1 and Table S1 
are available at http://www.jem.org/cgi/content/full/jem.20052454/DC1.
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